Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review

Cancer therapies targeting human epidermal growth factor receptor 2 (HER2) have been attracting increasing attention worldwide, especially in lung adenocarcinoma. Disitamab vedotin is an antibody-drug conjugate designed for targeting HER2 that has been approved for urothelial carcinoma and gastric c...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Xiangjun Qi, Jiayun Guo, Xiaoqi Zhou, Lingling Sun, Jietao Lin, Zijing Huang, Hanrui Chen, Lizhu Lin
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2022-09-01
Rangatū:	Heliyon
Ngā marau:	Disitamab vedotin Antibody-drug conjugate Lung adenocarcinoma Human epidermal growth factor receptor 2
Urunga tuihono:	http://www.sciencedirect.com/science/article/pii/S2405844022018692
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!